KẾT QUẢ HOÁ XẠ TRỊ TRIỆT CĂN SAU HOÁ CHẤT CẢM ỨNG Ở BỆNH NHÂN UNG THƯ VÒM MŨI HỌNG GIAI ĐOẠN T4

Abstract

Objectives: To evaluate the outcomes of definitive chemoradiotherapy following induction chemotherapy in patients with stage T4M0 nasopharyngeal carcinoma (NPC). Methods: A cross-sectional descriptive study was conducted on 60 patients at Vietnam National Cancer Hospital (K Hospital) from November 2020 to December 2022. All patients received three complete cycles of induction chemotherapy with either the GC regimen (Gemcitabine 1,000 mg/m² on days 1 and 8; Cisplatin 80 mg/m² on day 1) or the TPF regimen (Docetaxel 60 mg/m² on day 1; Cisplatin 60 mg/m² on day 1; Fluorouracil 600 mg/m² on days 1 - 5), followed by concurrent chemoradiotherapy with Cisplatin administered either weekly or every three weeks. Results: All patients completed three cycles of induction chemotherapy with either the TPF or GC regimen. Intensity-modulated radiotherapy (IMRT) was the predominant radiation technique employed in this study, accounting for 90% of cases. At one month post-chemoradiotherapy, the complete response and partial response rates were 78.33% and 21.67%, respectively. The median follow-up duration was 39 months (range, 11 - 56 months). The 3-year disease-free survival and overall survival rates were 88.33% and 76.67%, respectively. Conclusion: Induction chemotherapy followed by Cisplatin-based concurrent chemoradiotherapy represents the standard treatment for patients with stage T4 NPC, providing relatively high disease-free survival and overall survival rates. However, tumor control in stage T4 disease remains challenging.